CoaguSense, a diagnostic device company, has unveiled a portable point-of-care Prothrombin Time/International Normalized Ratio (PT/INR) analyzer to directly detect blood clotting time for patients stabilized on oral anti-coagulation medications such as Coumadin or warfarin. The CoaguSense PT/INR monitoring system has now been cleared by US FDA for use by patients in the home by prescription.
CoaguSense PT/INR monitoring system consists of a low-cost meter and disposable test strip. Medical professionals can order the system through Abbott Point of Care, which formed an exclusive agreement with CoaguSense to sell and market.
Doug Patterson, president and CEO of CoaguSense, said: “CoaguSense was formed to address an important need for patients requiring the oral anticoagulant warfarin on a long-term basis. By offering suitable patients the ability to test weekly at home with the CoaguSense PT/INR Monitoring System, patients and their doctors can have greater confidence that therapy is being properly monitored.
“The CoaguSense system’s direct micromechanical blood clot detection technology brings performance and reliability to a market that has traditionally been challenged by products employing indirect means of detecting clot formation.”